friends of FSH Research

Tagline

Search News Items

Therapy Q&A

Interview of Dr. Joel Chamberlain regarding her lab's work on therapy development.
Thanks to Dr. Joel Chamberlain (University of Washington, Seattle) who answered our questions about the work that she and her lab are doing to better understand FSHD and develop su… http://fshfriends.org/blog/therapy-q/

Potential use of BET inhibitors for FSHD

Q&A by Fran Sverdrup, a Research Fellow at Center for World Health and Medicine.
What are BET inhibitors?  BET inhibitors are a class of drugs with anti-inflammatory and anti-cancer properties. Although no BET inhibitors are yet approved for use in the US or i… http://fshfriends.org/blog/potential-use-bet-inhibitors-fshd/

FSHD Respiratory Issues

Interview with Dr. Nicholas S. Hill, Chief of the Pulmonary, Critical Care, and Sleep Division at Tufts University School of Medicine.
We sat down with Dr. Nicholas S. Hill, Chief of the Pulmonary, Critical Care, and Sleep Division at Tufts University School of Medicine to learn more about his work to improve the… http://fshfriends.org/blog/fshd-respiratory-issues/

FSHD Registry

Dr. Rabi Tawil discusses the National Registry based in Rochester, NY.
What is the purpose of the National Registry of FSHD Patients and Family Members and how does it work? The FSHD Registry was created in 2000 with funding from NIH. Its purpose … http://fshfriends.org/blog/fshd-registry/

Serum Biomarkers

Sheila had the pleasure of meeting with Daniel G. Miller, Geneticist at Seattle Children’s Hospital, and Associate Professor at the University of Washington. Dr. Miller and colleagues from the University of Rochester, the University of Washington, and Sea…
Interview with Research Dr. Daniel Miller on June 2 2016 Sheila had the pleasure of meeting with Daniel G. Miller, Geneticist at Seattle Children’s Hospital, and Associate … http://fshfriends.org/blog/serum-biomarkers/